Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna shares fall after FDA refuses to review new flu vaccine
02:29am, Wednesday, 11'th Feb 2026
Moderna shares opened 14% lower in Frankfurt on Wednesday in low volume after the U.S. Food and Drug Administration refused to review the company's approval application for its influenza vaccine.
The company said the agency wouldn't review its application on the grounds that the study testing the shot wasn't sufficient.
Moderna says US FDA refuses to review its influenza vaccine
06:08pm, Tuesday, 10'th Feb 2026
Moderna said on Tuesday the U.S. Food and Drug Administration will not review its approval application for its influenza vaccine.
Moderna says FDA refuses to review its application for experimental flu shot
06:03pm, Tuesday, 10'th Feb 2026
The Food and Drug Administration refused to start a review of Moderna's application for its experimental flu shot, the company said. It's another sign of the Trump administration's influence on tighte
Moderna Plunges After FDA Rejects Its Messenger-RNA-Based Flu Shot
06:00pm, Tuesday, 10'th Feb 2026
The FDA rejected Moderna's experimental flu vaccine Tuesday in a move that proved to be a blow to recently hot Moderna stock.
The FDA has refused to review Moderna's application to sell a new flu shot, the latest move by the administration against vaccines
06:00pm, Tuesday, 10'th Feb 2026
The company said the agency wouldn't review its application on the grounds that the study testing the shot wasn't sufficient.
Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type A meeting to understand the path forward mRNA-1010 has been
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
07:00am, Tuesday, 10'th Feb 2026
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security Strategic agreement will enable access to Modern
Should You Buy Moderna Before Feb. 13?
11:15pm, Monday, 09'th Feb 2026
Moderna's shares have performed well this year, driven by clinical and regulatory progress. The company's results being reported on Friday won't be particularly strong, especially as its core market f
Moderna (MRNA) Laps the Stock Market: Here's Why
06:45pm, Monday, 09'th Feb 2026
In the latest trading session, Moderna (MRNA) closed at $41.95, marking a +2.29% move from the previous day.
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
12:41pm, Monday, 09'th Feb 2026
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?
08:55am, Monday, 09'th Feb 2026
MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:01am, Friday, 06'th Feb 2026
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
10:01am, Friday, 06'th Feb 2026
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Tom Gardner's 2026 Outlook: Volatility, Government Scrutiny, and Two AI-Adjacent Stocks
04:29pm, Wednesday, 04'th Feb 2026
Tom Gardner outlines two selective AI opportunities and a disciplined portfolio framework for the next three to five years.
